Skip to main content

Table 1 Characteristics of AD patients and controls

From: Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease

Subject details Controls (n = 22) AD patients (n = 37) p value
Gender (F/M), no (%) 10(45)/12(55) 19(53)/18(47) 0.6
Age, years (mean ± SD) 69.2 ± 8.0 70.51 ± 7.5 0.54
MMSE score (median IQR) 29.00(26.50-29.00) 22.00(18.00-25.00 <0.0001
APOE ε4 positive (%) 33 % 67 % 0.0002
Plasma CRP (mg/L), median (IQR) 2.095 (0.8425 – 4.7535) n = 16 1.020 (0.6500 – 1.295) n = 25 0.0543
CSF Biomarkers
Aβ1-42 (pg/ml), median (IQR) 978.5(821.8-1045) 367.0(301.0-433.0) <0.0001
T-tau (pg/ml), median (IQR) 239.5(196.3-279.0) 596.0(455.0-858.5) <0.0001
P-tau181 (pg/ml), median (IQR) 45.0(36.8-58.3) 95.0(75.0-111.5) <0.0001
T-tau/Aβ1-42 ratio, median (IQR) 0.25(0.19-0.33) 1.56(1.24-2.55) <0.0001
sTREM2 (pg/ml), median (IQR) 195.6(131.0-240.7) 231.2(172.5-305.4) 0.0457
  1. Data expressed as mean ± SD or median (IQR) as appropriate. Probability values (p) denote differences between control and AD. A χ2 test was used for gender and APOE genotype comparisons. CSF biomarkers and sTREM2 were evaluated using the Mann-Whitney U test